Last reviewed · How we verify
Parkinson's disease
Approved treatments
- Pagitane · Eli Lilly
- Inbrija · Merz
Levodopa works by crossing the blood-brain barrier and being converted into dopamine, a neurotransmitter that helps regulate movement and coordination. - FOSCARBIDOPA · AbbVie GK
Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease. - FOSLEVODOPA · AbbVie GK
Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease. - Sinemet Cr · Aton
Levodopa crosses the blood-brain barrier and is converted to dopamine in the brain, relieving Parkinson's disease symptoms. - Selegiline Hydrochloride · Somerset
- Apokyn · Mdd Us
- Parlodel · Esjay Pharma
- Northera · Lundbeck Na Ltd
Northera works by increasing the levels of certain neurotransmitters in the brain, such as norepinephrine, to help regulate blood pressure and movement. - Ongentys · Neurocrine Biosciences
Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain. - Artane
- Nuplazid · Acadia Pharms Inc
Nuplazid works by blocking the action of a specific chemical messenger in the brain called serotonin. - Neupro · UCB
Rotigotine stimulates dopamine receptors in the brain, which may help treat Parkinson's disease and Restless Legs Syndrome. - Comtan · Orion Pharma
Comtan works by blocking the enzyme catechol-O-methyltransferase, which breaks down dopamine in the brain. - APOKYN · MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Lodosyn · University of Miami
- Requip · GSK
- Cogentin · University of Southern California
- Northera · The Cooper Health System
- Artane
- Domin
- Requip · Boehringer Ingelheim
- Kemadrine
- Akineton · AbbVie
- Nourianz · Kyowa Kirin
Nourianz works by blocking the adenosine receptor A2a, which helps to increase dopamine levels in the brain. - Gocovri · Endo
- Cogentin
- Xadago · Mdd Us
Xadago works by blocking the enzyme amine oxidase [flavin-containing] B, which breaks down dopamine in the brain. - Azilect · Teva
- GOCOVRI · Oregon Health and Science University
- Ongentys · Bial - Portela C S.A.
- Amantadin · Centre Hospitalier Universitaire de Nice
- Zelapar · Baylor College of Medicine
- Bromocriptin · University Hospital, Bonn
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Parkinson's disease patent landscape — cliff calendar, originator estates, attackable patents
- Parkinson's disease treatment landscape brief
- Parkinson's disease treatment updates RSS
Frequently asked questions about Parkinson's disease
What drugs treat Parkinson's disease?
Tracked treatments include Pagitane, Inbrija, FOSCARBIDOPA, FOSLEVODOPA, Sinemet Cr, Selegiline Hydrochloride, Apokyn, Parlodel.
What is the treatment for Parkinson's disease?
Standard treatment for Parkinson's disease includes Pagitane, Inbrija, FOSCARBIDOPA, FOSLEVODOPA, Sinemet Cr. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Parkinson's disease patent cliff · Parkinson's disease CI report
- Treatment: Pagitane · Eli Lilly
- Treatment: Inbrija · Merz
- Treatment: FOSCARBIDOPA · AbbVie GK
- Treatment: FOSLEVODOPA · AbbVie GK
- Treatment: Sinemet Cr · Aton
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing